Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (RARE) for alleged material misstatements and omissions regarding its drug setrusumab, affecting investors who purchased stock between August 3, 2023, and December 26, 2025 [1] Summary by Relevant Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the Northern District of California, under the case name Bailey v. Ultragenyx Pharmaceutical Inc., Case No. 3:26-cv-01097 (N.D. Cal.) [1] - Investors have until April 6, 2026, to file for lead plaintiff status [1] Allegations - The complaint alleges that Ultragenyx misrepresented the reliability of information regarding the effects of setrusumab on patients with Osteogenesis Imperfecta, downplaying the risks associated with the Phase III Orbit study [1] - It is claimed that Ultragenyx's optimism regarding the study results was unfounded, as the Phase II results lacked a placebo control group, raising concerns about the validity of the reported reduction in annualized fracture rate (AFR) [1] - The lawsuit asserts that the positive statements made by Ultragenyx about its business and prospects were materially misleading and lacked a reasonable basis [1] Investor Actions - Investors are advised to retain counsel or contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation [1] - The process for becoming a lead plaintiff is outlined, emphasizing that the lead plaintiff represents the interests of all class members [1]

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of The Estee Lauder Companies, Inc. which may affect shareholder rights [1] Group 1: Shareholder Rights and Legal Options - Long-term shareholders of Estee Lauder may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2] - Shareholder involvement is crucial for improving company policies and practices, leading to enhanced shareholder value [3] Group 2: Legal Representation and Firm Background - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, recovering millions for defrauded investors [4] - The firm operates on a contingent fee basis, meaning clients do not pay out-of-pocket legal fees or expenses [2]

Core Viewpoint - A securities fraud class action lawsuit has been initiated against Masonite International Corporation, alleging misrepresentations related to stock purchase offers from Owens Corning, affecting investors who sold shares between June 5, 2023, and February 8, 2024 [4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who sold Masonite common stock during the specified period [4]. - The allegations include violations of the Securities Exchange Act of 1934 against Masonite and certain senior officers [4]. Group 2: Legal Participation - Investors who sold Masonite stock can join the class action lawsuit and must file to serve as lead plaintiff by April 7, 2026 [3]. - Participation as a lead plaintiff is not required to share in any potential recovery, and all representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. Group 3: Law Firm Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its inception in 1993 and has a strong track record in class action litigation [5].

Core Viewpoint - A securities fraud class action lawsuit has been initiated against BlackRock TCP Capital Corp., with a deadline for potential lead plaintiffs set for April 6, 2026 [1][3][4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Central District of California on behalf of investors who purchased or acquired BlackRock securities between November 6, 2024, and January 23, 2026, alleging violations of the Securities Exchange Act of 1934 [4]. - The allegations include misrepresentations made by the defendants regarding the valuation of the Company's investments [4]. Group 2: Participation Information - Investors who wish to join the class action or discuss their legal rights can contact the Investor Relations Manager or visit the designated website [2][7]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [3].

Core Viewpoint - A class action lawsuit has been filed against SLM Corporation (Sallie Mae) on behalf of investors who acquired its securities during the specified Class Period, alleging misleading information regarding loan delinquencies [1][3]. Group 1: Lawsuit Details - The lawsuit claims that during the Class Period from July 25, 2025, to August 14, 2025, Sallie Mae misled investors about the rise in loan delinquencies, asserting that the increase was typical for seasonal patterns [3]. - The complaint highlights that despite the rise in delinquencies, the company promoted its loss mitigation and loan modification efforts as successful [3]. - Investors became aware of the true state of Sallie Mae's loan portfolio following a TD Cowen report on August 14, 2025, which indicated a 49-basis-point month-over-month increase in delinquencies, surpassing seasonal norms [4]. Group 2: Stock Impact - Following the revelation of the actual delinquency rates, Sallie Mae's stock price fell by $2.67 per share, representing an 8.09% decline, closing at $30.32 on August 15, 2025 [4]. Group 3: Investor Information - Investors who purchased Sallie Mae securities during the Class Period have until February 17, 2026, to seek appointment as lead plaintiff representatives [2]. - The law firm Berger Montague PC is leading the class action and provides contact information for interested investors [5].

Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Denha v. BellRing Brands, Inc., No. 1:26-cv-00575 [3]. - Investors have until March 23, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - BellRing Brands develops, markets, and sells "convenient nutrition" products, primarily under the Premier Protein brand, including ready-to-drink protein shakes [4]. - The company previously claimed that its sales growth was due to increased consumer demand and organic growth, while downplaying competitive pressures [4]. Group 3: Stock Performance and Impact - On May 6, 2025, BellRing's CFO indicated that several key retailers had lowered their inventory levels, leading to a stock price drop of $14.88 per share, or 19%, from $78.43 to $63.55 [5]. - Following the release of its 3Q 2025 financial results on August 4, 2025, and subsequent earnings call, BellRing's stock fell by $17.46 per share, nearly 33%, from $53.64 to $36.18 [6][7].

Core Viewpoint - A class action lawsuit has been filed against Plug Power Inc. and its senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Plug Power specializes in hydrogen fuel cell turnkey solutions for electric mobility and stationary power markets, and develops infrastructure such as hydrogen production plants [4]. Legal Proceedings - Investors have until April 3, 2026, to request to lead the case, which is pending in the U.S. District Court for the Northern District of New York, captioned Ortolani v. Plug Power Inc., et al., No. 1:26-cv-00165 [3]. Financial Impact - Plug Power announced a $1.66 billion loan guarantee from the U.S. Department of Energy to finance the construction of hydrogen production projects, but allegedly overstated the likelihood of receiving these funds [4]. - The stock price dropped significantly following key announcements: - On October 7, 2025, the abrupt departure of CEO Andrew Marsh and President Sanjay Shrestha led to a 6.3% drop, from $4.13 to $3.87 per share [5]. - On November 10, 2025, the suspension of activities under the DOE loan program caused a 3.4% drop, from $2.65 to $2.56 per share [6]. - On November 14, 2025, confirmation of the suspension of plans to construct hydrogen facilities resulted in a 17.6% drop, from $2.49 to $2.25 per share [7].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Company Overview - Ardent Health operates acute care hospitals and other healthcare facilities, with a focus on the collection of accounts receivable [4]. Allegations of Fraud - The lawsuit claims that Ardent Health misrepresented its process for determining the collectability of accounts receivable, stating it relied on "detailed reviews of historical collections," while in reality, it used a "180-day cliff" method that inflated reported accounts receivable and delayed loss recognition [4]. Stock Performance Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 on November 13, 2025 [5]. Legal Proceedings - Investors have until March 9, 2026, to request to lead the case in the U.S. District Court for the Middle District of Tennessee, under the caption Postiwala v. Ardent Health, Inc., et al. [3].

Core Viewpoint - PennyMac Financial Services, Inc. is under investigation for potential violations of federal securities laws related to its mortgage recapture efforts as interest rates declined [1][2][3]. Company Overview - PennyMac originates and services home mortgages and has recently increased its capacity to originate loans to retain borrowers seeking to refinance [2]. - The company has publicly claimed improvements in its recapture rates during this period [2]. Investigation Details - The investigation by Bleichmar Fonti & Auld LLP focuses on whether PennyMac misrepresented its ability to recapture customers refinancing their mortgages [3]. Financial Performance - On January 29, 2026, PennyMac reported disappointing financial results for Q4 2025, revealing that increased origination capacity was not sufficient due to heightened competition in the market [4]. - Following the earnings call, PennyMac's stock price dropped over 37%, from $140.70 per share to as low as $93.50 per share [4].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for securities fraud, alleging that the company misled investors regarding the efficacy of its drug setrusumab in clinical trials [1] Group 1: Lawsuit Details - The lawsuit covers purchasers of Ultragenyx common stock from August 3, 2023, to December 26, 2025, and claims that the company provided misleading information about the expected results of its Phase III Orbit and Cosmic Studies [1] - Defendants allegedly made positive statements about setrusumab's ability to reduce annualized fracture rates in Osteogenesis Imperfecta patients while concealing material adverse facts about the drug's true potential [1] - The lawsuit asserts that these misleading statements led to Ultragenyx securities being purchased at artificially inflated prices, resulting in investor damages when the truth was revealed [1] Group 2: Legal Representation - Investors wishing to join the class action can do so without any out-of-pocket fees through a contingency fee arrangement [1] - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and encourages selecting qualified counsel with a proven track record [1] - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 alone [1]